![Eric Hyllengren](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 156 791 $ in data 31/08/2026
Eric Hyllengren is currently Chief Financial & Accounting Officer at Tenaya Therapeutics, Inc. since 2026.
Formerly, Mr. Hyllengren was Chief Financial & Accounting Officer at Zura Bio Ltd. from 2025 to 2026, Chief Financial, Operating & Accounting Officer at Atara Biotherapeutics, Inc. from 2024 to 2025, and Executive Director-Business Development at Amgen, Inc. from 2017 to 2018.
Mr. Hyllengren completed undergraduate studies at the University of Notre Dame and earned an MBA from Kellogg School of Management.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 10/03/2026 | 17.617 ( 0,18% ) | 156 791 $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| TENAYA THERAPEUTICS, INC. | Direttore Finanziario/CFO | 13/07/2026 |
| Società | Posizione | Fine |
|---|---|---|
| ZURA BIO LIMITED | Direttore Finanziario/CFO | 20/04/2026 |
| ATARA BIOTHERAPEUTICS, INC. | Direttore Finanziario/CFO | 31/03/2025 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2018 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 6 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Tenaya Therapeutics, Inc.
 Tenaya Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for heart failure | Health Technology |
Zura Bio Ltd.
 Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
